According to the latest report published by Data Bridge Market Research, the Antisense Oligonucleotide for Cardiometabolic Disorders Market The global antisense oligonucleotide for cardiometabolic disorders market size was valued at USD 310.32 million in 2024 and is expected to reach USD 1,135.19 million by 2032, at a CAGR of 17.60% during the forecast period With the use of...